Aerogen Pharma and Lyomark Pharma have announced a partnership for development and commercialization of AP-002, a nasally-inhaled surfactant based on Lyomark's Alveofact bovine lung surfactant for the treatment of respiratory distress syndrome (RDS) in pre-term infants. According to Aerogen, the company has also initiated a Phase 2 study of AP-002 in Australia, with … [Read more...] about Aerogen and Lyomark Pharma partner on nasally-inhaled surfactant for RDS
Business
Airware Labs agrees to acquire cannabis company for development of intranasal THC
Airware Labs Corporation has entered into a non-binding letter of intent to acquire a cannabis consulting company and grower doing business as Item 9 Labs with the goal of developing an intranasal THC product, Airware Labs Corp said. The agreement would be terminated if the two companies are unable to finalize terms by the end of the year. All of the products … [Read more...] about Airware Labs agrees to acquire cannabis company for development of intranasal THC
Savara gets $5 million from CFFT for AeroVanc development
Savara has received a development award of up to $5 million from Cystic Fibrosis Foundation Therapeutics (CFFT), which will support the Phase 3 AVAIL study of the AeroVanc DPI for the treatment of MRSA lung infections in cystic fibrosis patients, the company said. In 2013, CFFT awarded the company $1.7 million for Phase 2 development of AeroVanc. Savara announced … [Read more...] about Savara gets $5 million from CFFT for AeroVanc development
Chiesi and Kamada end agreement for European distribution of inhaled AAT
Kamada has announced that an agreement with Chiesi for European distribution of Kamada's inhaled Alpha-1 Antitrypsin (AAT) has been terminated. According to Kamada, the companies mutually agreed to end the agreement because Kamada recently withdrew its MAA for inhaled AAT, and "a European distribution agreement within the pact’s defined timeframe is not currently … [Read more...] about Chiesi and Kamada end agreement for European distribution of inhaled AAT
Innovus launches FlutiCare OTC nasal spray in US
Innovus Pharmaceuticals says that it has launched FlutiCare fluticasone propionate nasal spray over the counter in the US in independent pharmacies and through its own online sites, as well as through Amazon and Walmart online stores. The company said that it plans to introduce the product in large retail stores in the next phase of the launch. Earlier this year, … [Read more...] about Innovus launches FlutiCare OTC nasal spray in US
Evoke Pharma selects Patheon for manufacture of Gimoti intranasal metoclopramide
Evoke Pharma has announced that has signed a 5-year agreement with CDMO Patheon for commercial manufacturing of Evoke's Gimoti intranasal metoclopramide for the treatment of diabetic gastroparesis. Patheon was acquired by Thermo Fisher earlier this year. In October 2017, Evoke announced that it plans to submit a 505(b)(2) NDA for Gimoti early in 2018 based on … [Read more...] about Evoke Pharma selects Patheon for manufacture of Gimoti intranasal metoclopramide
Neurelis gets Japanese patent for intranasal diazepam formulation
The Japan Patent Office has allowed JP Application No. 2014-515967 which covers Neurelis' NRL-1 intranasal diazepam formulation, the company said. In January 2017, Neurelis received Fast Track designation from the US FDA for NRL-1, which had previously received Orphan Drug designation in 2015. The company announced the initiation of pivotal trials for NRL-1 for … [Read more...] about Neurelis gets Japanese patent for intranasal diazepam formulation
Bayer launches line of pediatric saline nasal sprays in US
Bayer has launched a line of saline nasal sprays for children aged 6 months and older in the US, the company said. The products, which include hydraSense Ultra-Gentle Nasal Mist, hydraSense Nasal Care Single-Use Vials and hydraSense Soft Comfort Tip Nasal Aspirator, are available exclusively at Walgreens drug stores. The company is promoting the products as "made … [Read more...] about Bayer launches line of pediatric saline nasal sprays in US
Theravance Biopharma opens corporate office in Dublin, Ireland
Theravance Biopharma has opened a corporate office in Dublin, Ireland and plans to hire 30 new employees over the next 2 years, the company said. The company also announced that it and its partner Mylan had presented additional data from 2 Phase 3 trials of TD-4208 inhaled revefenacin at the 2017 CHEST meeting. Topline results from the Phase 3 trials were released … [Read more...] about Theravance Biopharma opens corporate office in Dublin, Ireland
Cyrano Therapeutics partners with Shanghai Newsummit on intranasal theophylline for hyposmia
Cyrano Therapeutics has announced a partnership agreement with Chinese CRO Shanghai Newsummit Biopharma (Newsummit) for development of Cyrano's intranasal theophylline for the treatment of taste and smell disorders in China. Newsummit will provide development services to a new Cyrano subsidiary called Wenzhou Cyrano, with the goal of approval by the … [Read more...] about Cyrano Therapeutics partners with Shanghai Newsummit on intranasal theophylline for hyposmia